BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Psoriatic Arthritis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Psoriatic Arthritis\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641089-104@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:sonelokimab: Phase 3 readout est. (NCT06641089)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: Evaluation
  of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα
  Inadequate Response\nEstimated primary completion: 4 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonelokimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06641089
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807424-19@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT06807424)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) 
 in Biologic-experienced and Biologic-naive Participants With Active Psoria
 tic Arthritis\nEstimated primary completion: 10 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06807424
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-92@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06506916)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarker
 s in Study Participants With Moderate to Severe Plaque Psoriasis\nEstimate
 d primary completion: 9 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06506916
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671483-101@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671483)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologi
 c Medicines\nEstimated primary completion: 18 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06671483
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671496-101@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671496)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been 
 Treated With Biologic Medicines\nEstimated primary completion: 18 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zasocitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06671496
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406035-52@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:TQH3906: Phase 2 readout est. (NCT07406035)
DESCRIPTION:TQH3906\, phase 2\, Psoriatic Arthritis.\nStudy: A Clinical Tri
 al of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07406035
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-6@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Stelara (ustekinumab): Phase 3 readout est. (NCT05092269)
DESCRIPTION:Stelara (ustekinumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-term Extension Study of Ustekinumab in Pediatric Participants\nEstim
 ated primary completion: 29 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05092269
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223138-104@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280204
DTEND;VALUE=DATE:20280205
SUMMARY:sonelokimab: Phase 3 readout est. (NCT07223138)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: A Study to
  Evaluate the Long-term Safety\, Tolerability\, and Efficacy of Subcutaneo
 us Sonelokimab in Participants With Psoriatic Arthritis\nEstimated primary
  completion: 4 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonelokimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07223138
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04804553-95@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04804553)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: Ap
 remilast Pediatric Study in Children With Active Juvenile Psoriatic Arthri
 tis\nEstimated primary completion: 21 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04804553
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668181-92@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06668181)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekiz
 umab in Pediatric Study Participants With Active Juvenile Idiopathic Arthr
 itis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankyl
 osing Spondylitis) and Juvenile Psoriatic Arthritis\nEstimated primary com
 pletion: 12 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bimekizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668181
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04991116-99@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ilumya (tildrakizumab): Phase 3 readout est. (NCT04991116)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 3\, Psoriatic Arthritis.\nStudy:
  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients 
 With Psoriatic Arthritis\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tildrakizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04991116
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-3@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06865105)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Psoriatic Arthritis.\nStudy:
  Study of Targeted Therapies for the Treatment of Adult Participants With 
 Active Psoriatic Arthritis\nEstimated primary completion: August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286058-101@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07286058)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: Continuati
 on Study of Zasocitinib in Adults With Psoriatic Arthritis\nEstimated prim
 ary completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07286058
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869551-100@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20300306
DTEND;VALUE=DATE:20300307
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06869551)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: A Study to Evaluate the Drug Levels\, Efficacy\, and Safety of Deucrav
 acitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Ar
 thritis\nEstimated primary completion: 6 March 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06869551
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871721-101@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20300418
DTEND;VALUE=DATE:20300419
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07871721)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)\nEstim
 ated primary completion: 18 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07871721
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663332-5@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20311212
DTEND;VALUE=DATE:20311213
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06663332)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants\nE
 stimated primary completion: 12 December 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06663332
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05767047-95@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20360317
DTEND;VALUE=DATE:20360318
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT05767047)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: A 
 Study of Apremilast in Children With Oral Ulcers Associated With Behçet's
  Disease or Juvenile Psoriatic Arthritis\nEstimated primary completion: 17
  March 2036. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apremila
 st#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5767047
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
